Startup profile · funding coverage
myNEO funding, valuation and investors
Computational target discovery and therapeutic design.
Keep track of myNEO
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · Ghent, Belgium
Overview
Belgian AI drug-discovery company using computational methods to identify targets and design therapies, with a collaboration history in mRNA research.
Why myNEO is interesting
Arcturus plans to integrate myNEO's computational platform into mRNA design and target identification, extending a collaboration that began in 2024.
Notable stories
- Arcturus Therapeutics signed a definitive agreement to acquire myNEO in September 2026; closing is expected in October subject to customary conditions.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.